C6orf58: A Potential Drug Target and Biomarker for Liver Enriched Gene 1 Homolog

Target Name: C6orf58

NCBI ID: G352999

C6orf58

C6orf58: A Potential Drug Target and Biomarker for Liver Enriched Gene 1 Homolog

Introduction

Liver enriched gene 1 (LIG1) is a non-coding RNA molecule that has been shown to play a crucial role in the regulation of various physiological processes in the liver. Mutations in the LIG1 gene have been linked to a range of diseases, including liver diseases, and are considered as potential drug targets. C6orf58, a non-coding RNA molecule that is closely related to LIG1, has been identified as a potential drug target and biomarker for LIG1-related diseases.

C6orf58 is a 21-nt RNA molecule that is highly conserved across various species, including humans. It is located between the 5' and 3' ends of the LIG1 gene and has been shown to play a role in the regulation of gene expression in various organisms. C6orf58 is composed of 11 exons that are predominantly encoded by the UTR3 region of the LIG1 gene.

Expression and Function of C6orf58

C6orf58 is highly expressed in various tissues and organs, including the liver, and is shown to play a role in the regulation of gene expression in the liver. Studies have shown that C6orf58 is highly expressed in the liver tissues, including the liver cortical, hepatocellular , and stromal cells. It is also shown to be involved in the regulation of gene expression in the liver, including the expression of genes involved in cell growth, apoptosis, and inflammation.

C6orf58 is also shown to play a role in the regulation of the expression of LIG1 itself. Studies have shown that C6orf58 can interact with LIG1 to enhance its expression and that this interaction may be involved in the regulation of various physiological processes in the liver.

Drug Target Potential

C6orf58 has been identified as a potential drug target for a range of liver diseases, including liver cancer, non-alcoholic steatohepatitis (NASH), and cirrhosis. This is because of its association with LIG1 regulation and the regulation of various physiological processes in the liver.

C6orf58 has been shown to be involved in the regulation of cell growth and apoptosis, which are important processes that are involved in the development and progression of many diseases. For example, studies have shown that C6orf58 is involved in the regulation of cell apoptosis in various tissues, including the liver. This may be because of its role in the regulation of apoptosis-related genes, including Bcl-2.

C6orf58 has also been shown to be involved in the regulation of inflammation, which is a key aspect of many diseases, including NASH and cirrhosis. Studies have shown that C6orf58 is involved in the regulation of the expression of pro-inflammatory genes, including NF-kappa-B and IL-1尾. This may be because of its role in the regulation of inflammation-related genes, including transcription factor-induced gene expression (TF-INFLAMMATORY).

Biomarker Potential

C6orf58 has also been identified as a potential biomarker for a range of liver diseases, including NASH and cirrhosis. This is because of its association with LIG1 regulation and the regulation of various physiological processes in the liver.

Studies have shown that C6orf58 is highly correlated with the expression of LIG1 in various tissues, including the liver. This may be because of its role in the regulation of LIG1 expression, which is involved in the regulation of various physiological processes in the liver.

Conclusion

C6orf58 is a non-coding RNA molecule that is closely related to LIG1 and has been shown to play a role in the regulation of various physiological processes in the liver. Its expression and function have been shown to be involved in the regulation of cell growth, apoptosis, and inflammation, which are important processes that are involved in the development and progression of many diseases. As a result, C6orf58 has been identified as a potential drug target and biomarker for LIG1-related diseases. Further studies are needed to fully understand its role in these processes and to develop effective therapies for these diseases.

Protein Name: Chromosome 6 Open Reading Frame 58

Functions: May be involved in early liver development

The "C6orf58 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C6orf58 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets